Výsledky vyhledávání - "Adelaida La Casta Munoa"

A phase II/III randomized double-blind study of octreotide acetate LAR with axitinib versus octreotide acetate LAR with placebo in patients with advanced G1-G2 NETs of non-pancreatic origin (AXINET trial-GETNE-1107)

Autor: Paula Jiménez Fonseca, Maria Jose Villanueva Silva, Carlos López-López, Ana Custodio, Salvatore Tafuto, Vega Iranzo, M. Benavent, Rocio Garcia-Carbonero, Adelaida La Casta Munoa, Alex Teulé, Jaume Capdevila, Enrique Grande, Teresa Alonso, Pilar García-Alfonso, Guillermo Crespo, Encarnación González, Francesca Spada, Daniel Castellano, Toni Ibrahim

Publikováno v: Journal of Clinical Oncology. 39:360-360

360 Background: Angiogenesis plays an important role in NET development and progression. Axitinib is a potent and selective VEGFR-1,2,3 inhibitor, with proven activity against several vascular-dependent solid tumors. The aim of this randomized, doubl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ddc4883f0a99b896faa4b517477d998d
https://doi.org/10.1200/jco.2021.39.3_suppl.360

Zobrazit plný text záznamu

Randomized phase II study on the influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab (Bev) or cetuximab (Cet), as first line therapy of patients (pts) with RAS wild-type metastatic colorectal carcinoma (mCRC) and <3 baseline circulating tumor cells (bCTCs)

Publikováno v: Journal of Clinical Oncology. 37:3549-3549

3549 Background: The outcome for mCRC has changed since the introduction of new chemotherapy schedules and targeted therapies, however new predictive biomarkers are needed. bCTCs and BRAF / PIK3CA mutations have been studied as a potential predictive

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c6e91a8c79997fe66c7ad506c85b34bf
https://doi.org/10.1200/jco.2019.37.15_suppl.3549

Zobrazit plný text záznamu

Final results of the TALENT trial (GETNE1509): a prospective multicohort phase II study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs)

Publikováno v: Journal of Clinical Oncology. 37:4106-4106

4106 Background: Approved systemic therapies for advanced NETs have showed limited tumor shrinkage and no data of activity after progression to prior targeted agents (TA) is available. Lenvatinib, a potent VEGFR1-3 & FGFR1-4 inhibitor may increase ef

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b6c38e2823615a672c73255aac9d3fb6
https://doi.org/10.1200/jco.2019.37.15_suppl.4106

Zobrazit plný text záznamu

Randomized phase III study comparing FOLFOX + bevacizumab versus folfoxiri + bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 baseline circulating tumor cells (bCTCs)

Publikováno v: Journal of Clinical Oncology. 37:3507-3507

3507 Background: FOLFOXIRI+BEV has demonstrated a survival benefit compared with FOLFIRI plus BEV (TRIBE Lancet Oncol 2015) in first-line mCRC. Nevertheless, due to its safety profile, this schedule is not recommended for all pts. In addition, we hav

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a2d02914911952b4ab67d86c7d1f8fb3
https://doi.org/10.1200/jco.2019.37.15_suppl.3507

Zobrazit plný text záznamu

Progression-free survival (PFS) and subgroups analyses of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs): Updated results from the phase II TALENT trial (GETNE 1509)

Publikováno v: Journal of Clinical Oncology. 37:332-332

332 Background: Pts with advanced G1/G2 NETs have limited treatment options with overall response rates (ORR) with targeted agents (TA) < 10%. Benefit on PFS after TA therapy has not been demonstrated. The mechanism of action of lenvatinib (VEGFR1-3

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0a9653539b1de28efcd8275a807dde27
https://doi.org/10.1200/jco.2019.37.4_suppl.332

Zobrazit plný text záznamu

Safety analysis of a phase III randomized trial comparing FOLFOX + Bevacizumab vs FOLFOXIRI + Bevacizumab as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 circulating tumor cells (CTCs) (VISNÚ-1 TTD TRIAL)

Publikováno v: Journal of Clinical Oncology. 36:3536-3536

3536Background: FOLFOXIRI plus bevacizumab has demonstrated a survival benefit compared with FOLFIRI plus bevacizumab (TRIBE Lancet Oncol 2015) in first-line mCRC. This schedule is not routinely re...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::67a5df6fe1731ed401ca8ab2203ed641
https://doi.org/10.1200/jco.2018.36.15_suppl.3536

Zobrazit plný text záznamu

Aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Safety and quality of life (QoL) data from the Spanish subgroup of the Aflibercept Safety and Quality-of-Life Program (ASQoP)

Autor: Carlos Fernández-Martos, Pablo Borrega, Mercedes Martinez Villacampa, Eduardo Polo Marques, Guillermo Lopez-Vivanco, Carmen Guillen, Jorge Aparicio, Pilar Alfonso, Rafael López, Adelaida La Casta Munoa, Fernando Rivera, Enrique Aranda, Laura Lema, Silvia Gil, A. Pisa

Publikováno v: Journal of Clinical Oncology. 35:751-751

751 Background: In the VELOUR trial, adding Z to FOLFIRI improves OS, PFS and RR in mCRC pts progressing after oxaliplatin ±biologic agents. The ASQoP trial (NCT01571284) was designed to gather safety and QoL data from mCRC in real-life setting. We

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::86572d00f12b3c922809c2e4ef9d332f
https://doi.org/10.1200/jco.2017.35.4_suppl.751

Zobrazit plný text záznamu

Correlation between RECIST-conventional imaging techniques, morphologic response by CT and histopathologic response, in hepatic metastasis secondary to colorectal cancer: The AVAMET study

Publikováno v: Journal of Clinical Oncology. 33:e14656-e14656

e14656 Background: The RECIST criteria may be limited in assessing response to biologic agents such as bevacizumab (BVZ). Retrospective studies of patients (pts) with colorectal liver metastases (C...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cd2d3151cd6e2f1b743eb307a212262a
https://doi.org/10.1200/jco.2015.33.15_suppl.e14656

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání